Biohaven (BHVN) Debt to Equity (2025 - 2026)
Biohaven's (BHVN) quarterly Debt to Equity came in at $1.87 in Q1 2026, down 59.28% quarter-over-quarter from $4.59 in Q4 2025.
Biohaven (BHVN) Debt to Equity (2025 - 2026) Analysis & Trends
Biohaven has disclosed Debt to Equity across 2 years of filings, most recently posting $1.87 for Q1 2026.
- Debt to Equity for Q1 2026 came in at $1.87, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $1.87 (changed N/A YoY), and the FY2025 annual result was $4.59, changed N/A from the prior year.
- Debt to Equity came in at $1.87 for Q1 2026 at Biohaven, down from $4.59 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $4.59 in Q4 2025 to a low of -$15.63 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 0.32 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Biohaven | 1.62 Bn | 1.27 Bn | - | 1.87 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.87 |
| Dec 31, 2025 | 4.59 |
| Sep 30, 2025 | -15.63 |
| Jun 30, 2025 | 1.64 |